Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of KJ101 injection for debridement of deep partial-thickness burn wounds
CTR20252263Phase 2Completed
- Sponsor
- Shanghai Baoji Pharmaceutical
- Start
- Aug 2025
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of KJ-101 in burn injury, wound, sponsored by Shanghai Baoji Pharmaceutical. Started Aug 2025; status: completed.
02
Drugs
KJ-101
03
Conditions
burn injurywound
Beyond the preview
Go deeper on CTR20252263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252263.